Search research articles
Contact Us
Filters
Showing results (601-610 of 754) with videos related to
Page
of 76
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 30, 2008
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
Christopher G Goetz, Joanne Wuu, Michael P McDermott, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 11, 2009
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease
Marian L Evatt, K Ray Chaudhuri, Kelvin L Chou, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 24, 2016
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
François Tison, Charlotte Keywood, Mark Wakefield, et al.
International Journal of Laboratory Hematology
|
February 7, 2024
Accuracy of automated analyzers for the estimation of CSF cell counts: A systematic review and meta-analysis
Greer E Waldrop, Kaitlyn Cocuzzo, Colleen L Schneider, et al.
Nature Reviews. Drug Discovery
|
May 3, 2011
Priorities in Parkinson's disease research
Wassilios G Meissner, Mark Frasier, Thomas Gasser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 17, 2004
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations
Christopher G Goetz, Werner Poewe, Olivier Rascol, et al.
Annals of Neurology
|
January 26, 2005
A responsive outcome for Parkinson's disease neuroprotection futility studies
Jordan J Elm, Christopher G Goetz, Bernard Ravina, et al.
Frontiers in Aging Neuroscience
|
June 1, 2022
Parkinson's Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
Michelle H S Tosin, Christopher G Goetz, Dharah P C F Bispo, et al.
American Journal of Medical Genetics. Part A
|
December 8, 2006
Neuropathic features in fragile X premutation carriers
Elizabeth Berry-Kravis, Christopher G Goetz, Maureen A Leehey, et al.
Archives of Neurology
|
February 15, 2001
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease
O Rascol, J G Nutt, O Blin, et al.
Page
of 76
Search research articles
Search
Showing results (601-610 of 754) with videos related to
Sort By:
Page
of 76
Movement Disorders : Official Journal of the Movement Disorder Society
|
January 30, 2008
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
Christopher G Goetz, Joanne Wuu, Michael P McDermott, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 11, 2009
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease
Marian L Evatt, K Ray Chaudhuri, Kelvin L Chou, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 24, 2016
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
François Tison, Charlotte Keywood, Mark Wakefield, et al.
International Journal of Laboratory Hematology
|
February 7, 2024
Accuracy of automated analyzers for the estimation of CSF cell counts: A systematic review and meta-analysis
Greer E Waldrop, Kaitlyn Cocuzzo, Colleen L Schneider, et al.
Nature Reviews. Drug Discovery
|
May 3, 2011
Priorities in Parkinson's disease research
Wassilios G Meissner, Mark Frasier, Thomas Gasser, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
September 17, 2004
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations
Christopher G Goetz, Werner Poewe, Olivier Rascol, et al.
Annals of Neurology
|
January 26, 2005
A responsive outcome for Parkinson's disease neuroprotection futility studies
Jordan J Elm, Christopher G Goetz, Bernard Ravina, et al.
Frontiers in Aging Neuroscience
|
June 1, 2022
Parkinson's Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
Michelle H S Tosin, Christopher G Goetz, Dharah P C F Bispo, et al.
American Journal of Medical Genetics. Part A
|
December 8, 2006
Neuropathic features in fragile X premutation carriers
Elizabeth Berry-Kravis, Christopher G Goetz, Maureen A Leehey, et al.
Archives of Neurology
|
February 15, 2001
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease
O Rascol, J G Nutt, O Blin, et al.
Page
of 76